Sourcebio International PLC
LSE:SBI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sourcebio International PLC
Depreciation & Amortization
Sourcebio International PLC
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sourcebio International PLC
LSE:SBI
|
Depreciation & Amortization
£2.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kooth PLC
LSE:KOO
|
Depreciation & Amortization
£6.2m
|
CAGR 3-Years
41%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genincode PLC
LSE:GENI
|
Depreciation & Amortization
£347k
|
CAGR 3-Years
105%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PHSC PLC
LSE:PHSC
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Iconic Labs PLC
LSE:ICON
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Trellus Health PLC
LSE:TRLS
|
Depreciation & Amortization
$865k
|
CAGR 3-Years
200%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sourcebio International PLC
Glance View
SourceBio International Plc engages in the provision of laboratory services in healthcare, clinical, life science research, and biopharma industries. The company is headquartered in Nottingham, Nottinghamshire. The company went IPO on 2020-10-29. The firm operates through four business segments: Infectious Disease Testing, Healthcare Diagnostics, Genomics and Stability Storage. Its Infectious Disease Testing segment offers COVID-19 antigen reverse transcription-polymerase chain reaction (RT-PCR) testing services to the national health service (NHS), private healthcare providers and private industry. Its Healthcare Diagnostics segment offers histopathology and clinical diagnostic services for the NHS and private healthcare across the United Kingdom and Ireland. Its Genomics segment offers deoxyribonucleic acid (DNA) sequencing services for pharmaceutical and biotechnology companies, academia, contract research organizations (CROs) and other research groups in the United Kingdom, Europe and North America. Its Stability Storage segment offers shelf-life testing services and equipment for pharmaceutical companies and others.
See Also
What is Sourcebio International PLC's Depreciation & Amortization?
Depreciation & Amortization
2.9m
GBP
Based on the financial report for Dec 31, 2021, Sourcebio International PLC's Depreciation & Amortization amounts to 2.9m GBP.
What is Sourcebio International PLC's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 3Y
-6%
Over the last year, the Depreciation & Amortization growth was 47%. The average annual Depreciation & Amortization growth rates for Sourcebio International PLC have been -6% over the past three years .
